Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?

Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, Atkins MB, Regan M, Signoretti S, Lenkinski RE, Goldberg SN.

Radiology. 2009 Jun;251(3):731-42. doi: 10.1148/radiol.2521081059. Erratum in: Radiology. 2009 Dec;253(3):900.

2.

Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.

Hakimé A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN.

Radiology. 2007 Aug;244(2):464-70.

PMID:
17641366
3.

Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).

De Bazelaire C, Rofsky NM, Duhamel G, Michaelson MD, George D, Alsop DC.

Acad Radiol. 2005 Mar;12(3):347-57.

PMID:
15766695
4.

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS.

J Transl Med. 2011 Dec 21;9:220. doi: 10.1186/1479-5876-9-220.

5.

Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings.

Lanzman RS, Robson PM, Sun MR, Patel AD, Mentore K, Wagner AA, Genega EM, Rofsky NM, Alsop DC, Pedrosa I.

Radiology. 2012 Dec;265(3):799-808. doi: 10.1148/radiol.12112260. Epub 2012 Oct 9.

6.

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

de Bazelaire C, Alsop DC, George D, Pedrosa I, Wang Y, Michaelson MD, Rofsky NM.

Clin Cancer Res. 2008 Sep 1;14(17):5548-54. doi: 10.1158/1078-0432.CCR-08-0417.

7.

Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.

Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, Signoretti S, Raptopoulos VD, Goldberg SN.

AJR Am J Roentgenol. 2008 Jul;191(1):133-9. doi: 10.2214/AJR.07.2848.

PMID:
18562736
8.

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS.

PLoS One. 2011 Apr 29;6(4):e19144. doi: 10.1371/journal.pone.0019144.

9.

Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.

Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, Takiguchi M, Tamaki N, Kuge Y.

Int J Oncol. 2012 Nov;41(5):1593-600. doi: 10.3892/ijo.2012.1624. Epub 2012 Sep 10.

10.

Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI.

Rajendran R, Huang W, Tang AM, Liang JM, Choo S, Reese T, Hentze H, van Boxtel S, Cliffe A, Rogers K, Henry B, Chuang KH.

Cancer Med. 2014 Feb;3(1):47-60. doi: 10.1002/cam4.177. Epub 2014 Jan 6.

11.

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M, Wood J, Martiny-Baron G, Unger C, Marmé D.

Cancer Res. 2000 Sep 1;60(17):4819-24.

12.

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.

Yuen JS, Sim MY, Siml HG, Chong TW, Lau WK, Cheng CW, Huynh H.

Br J Cancer. 2011 Mar 15;104(6):941-7. doi: 10.1038/bjc.2011.55.

13.

Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.

Cyran CC, Paprottka PM, Schwarz B, Sourbron S, Ingrisch M, von Einem J, Pietsch H, Dietrich O, Hinkel R, Bruns CJ, Reiser MF, Wintersperger BJ, Nikolaou K.

AJR Am J Roentgenol. 2012 Feb;198(2):384-91. doi: 10.2214/AJR.11.6951.

PMID:
22268182
14.

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.

Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O.

Mol Cancer. 2011 Jul 26;10:90. doi: 10.1186/1476-4598-10-90.

15.

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM.

J Clin Oncol. 2008 Oct 1;26(28):4572-8. doi: 10.1200/JCO.2007.15.5655.

16.

Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM.

Neoplasia. 2009 Sep;11(9):910-20.

17.

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.

Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S.

Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74. Epub 2006 Dec 8.

PMID:
17160391
18.

Acute kidney injury: arterial spin labeling to monitor renal perfusion impairment in mice-comparison with histopathologic results and renal function.

Hueper K, Gutberlet M, Rong S, Hartung D, Mengel M, Lu X, Haller H, Wacker F, Meier M, Gueler F.

Radiology. 2014 Jan;270(1):117-24. doi: 10.1148/radiol.13130367. Epub 2013 Oct 28.

PMID:
24023073
19.

Magnetic resonance imaging as a biomarker in renal cell carcinoma.

Pedrosa I, Alsop DC, Rofsky NM.

Cancer. 2009 May 15;115(10 Suppl):2334-45. doi: 10.1002/cncr.24237. Review.

20.
Items per page

Supplemental Content

Write to the Help Desk